Sitagliptin (Januvia)

DRUG4 trials

Sponsors

Ludwig-Maximilians - University of Munich, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University College Dublin, Kafrelsheikh University

Conditions

Acute Myocardial InfarctionDiabetes Mellitus Type 1Diabetes Mellitus Type 2Liver Cirrhosis With DiabetesPsoriasis

Phase 1

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

CompletedNCT00813228

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Diabetes Mellitus Type 1, Diabetes Mellitus Type 2

Start: 2009-01-06End: 2019-11-26Updated: 2019-11-29

Phase 2

Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction

CompletedNCT00650143

Ludwig-Maximilians - University of MunichAcute Myocardial Infarction

Start: 2008-03-31End: 2013-06-30Updated: 2022-08-25

Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)

CompletedNCT02347501

University College DublinPsoriasis

Start: 2013-11-30End: 2016-12-31Updated: 2017-04-28

Phase 4

Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis

CompletedNCT07439536

Kafrelsheikh UniversityLiver Cirrhosis With Diabetes

Start: 2024-07-01End: 2025-10-01Updated: 2026-02-27

Related Papers

Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.

2016-01-1510 citations

Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial).

2015-11-3019 citations

Abstract 12114: Safety and Efficacy of Sitagliptin plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction (Sitagrami Trial) - Primary and Secondary Analyses

Circulation2015-11-10